This article is more than 5 years old. Information may no longer be current.

PROSE lens and autologous tears can treat persistent epithelial defects

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WAILEA, Hawaii — The combination of a scleral lens and autologous serum tears can effectively treat patients with refractory cases of persistent epithelial defects, according to a speaker here.

“The PROSE (prosthetic replacement of the ocular surface ecosystem) lens has been a miracle for a lot of patients who haven’t responded to treatment for dry eye disease or some other form of ocular surface disease,” Kendall E. Donaldson, MD, MS, said at Hawaiian Eye 2018.

In a case series, three patients with persistent epithelial defects who were refractory after being treated with drops, preservative-free products, various forms of lid augmentation procedures and other standard treatments were evaluated after being treated with a PROSE device, moxifloxacin and preservative-free saline, and autologous hematopoietic products, Donaldson said.

Patients wore the PROSE device at all times, except for lens cleaning and replacement of reservoir contents every 12 hours. The first patient experienced a resolution of the defect in 29 days, the second patient experienced a resolution of the defect in 10 days, and the third patient resolved over 5 days, she said.

“We have a study that showed in about 85% of patients that were refractory to all other commercial treatments, they had a very good response to our serum tears. That in combination with the PROSE device can really be miraculous. We just wanted to demonstrate the efficacy of the combination of two different technologies and treatments to help these refractory epithelial defects. Both of these are very helpful and in conjunction they can be life-changing for these challenging patients,” she said. – by Robert Linnehan

Reference:

Donaldson KE. The combined use of scleral lenses and autologous tears in the treatment of non-healing epithelial defects. Presented at: Hawaiian Eye 2018; Jan. 13-19, 2018; Wailea, Hawaii.

Disclosure: Donaldson reports consulting fees with Abbot Medical Optics/Johnson & Johnson, Alcon, Allergan, Bausch + Lomb, Bio-Tissue, Omeros, Shire, Sun and TearLab.